Mallory, Katherine L.
Taylor, Justin A.
Zou, Xiaoyan
Waghela, Ishita N.
Schneider, Cosette G. http://orcid.org/0000-0001-5825-7640
Sibilo, Michael Q.
Punde, Neeraja M.
Perazzo, Leah C.
Savransky, Tatyana
Sedegah, Martha
Dutta, Sheetij
Janse, Chris J.
Pardi, Norbert
Lin, Paulo J. C.
Tam, Ying K.
Weissman, Drew
Angov, Evelina http://orcid.org/0000-0001-9186-4098
Funding for this research was provided by:
United States Department of Defense | United States Army | U.S. Military Academy
United States Agency for International Development
U.S. Military Infectious Diseases Research Program (MIDRP) U.S. Agency for International Development
Acuitas Therapeutics
Article History
Received: 23 November 2020
Accepted: 24 May 2021
First Online: 18 June 2021
Competing interests
: Paulo J.C. Lin and Ying Tam are employees of Acuitas Therapeutics, a company focused on the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic applications. Ying Tam is named on patents describing the use of modified mRNA lipid nanoparticles. In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Norbert Pardi and Drew Weissman are named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. EA, SD and MS are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as work prepared by a military Service member or employee of the U.S. Government as part of that person’s official duties.